Understanding insulin sensitivity in breast cancer survivors
Study of Molecular Causes of Metabolic Disorders in Obese Premenopausal Women After Breast Cancer
This study tests how insulin resistance affects the metabolic health of premenopausal women who have survived breast cancer and compares them to healthy women.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 20 Years to 45 Years |
| Sex | Female |
| Sponsor | University of Copenhagen Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Copenhagen, DK) |
| Trial ID | NCT05010356 on ClinicalTrials.gov |
What this trial studies
This study investigates the metabolic disorders, particularly insulin resistance, that affect women who have survived breast cancer. It aims to determine how insulin resistance in skeletal muscle contributes to these metabolic issues and to identify molecular changes induced by breast cancer or its treatment. By focusing on premenopausal women who have completed chemotherapy, the study seeks to fill a significant gap in understanding the physiological effects of breast cancer on metabolic health. Healthy controls will also be included for comparison, matched by gender, weight, age, and physical activity levels.
Who should consider this trial
Good fit: Ideal candidates are premenopausal women who have undergone surgery for breast cancer and completed adjuvant chemotherapy within the last three weeks.
Not a fit: Patients who are postmenopausal, have a history of type 2 diabetes, or have cardiovascular disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of metabolic disorders in breast cancer survivors, potentially reducing recurrence and mortality rates.
How similar studies have performed: While there is limited research specifically on breast cancer survivors, studies on metabolic disorders in cancer patients have shown promising results, indicating that this approach is both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Premenopausal women operated for breast cancer and after completing adjuvant chemotherapy and no earlier than 3 weeks after its termination * BMI: 25-30 * Healthy controls will be included matched by gender, weight, age, and level of physical activity to the patient group included as subjects Exclusion Criteria: * Known postmenopause occurred at the time of diagnosis of breast cancer * Alcohol intake of\> 7 items / week * Smoker * Already known Type 2 diabetes mellitus or metabolic syndrome and medical treatment thereof. * Cardiovascular disease and its medical treatment * Impaired mobility
Where this trial is running
Copenhagen, DK
- University of Copenhagen — Copenhagen, Dk, Denmark (Recruiting)
Study contacts
- Principal investigator: Lykke Sylow, PhD — University of Copenhagen
- Study coordinator: Lykke Sylow, PhD
- Email: Lykkesylow@sund.ku.dk
- Phone: 20955250
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.